Overexpression of LINC01234 in uterus corpus endometrial cancer correlated with poor clinicopathological characteristics: a study based on TCGA data

Uterus corpus endometrial cancer (UCEC) is associated with a high mortality rate. In this study, we examined the impact of long intergenic non-protein coding RNA 01234 (LINC01234) in the diagnosis and survival of UCEC using an open high-throughput sequencing database. The association between LINC01234 expression and UCEC clinical features was determined using the Wilcoxon rank sum test, logistic regression and Cox regression. To assess the classification effectiveness of LINC01234 in UCEC, the area under the receiver operating characteristic (ROC) curve (AUC) was performed. Then, Kaplan-Meier analysis was performed to determine the prognostic significance of LINC01234 in UCEC. The underlying regulatory mechanisms of LIN01234 were assessed using the Gene set enrichment analysis (GSEA), and the influence on immune infiltration cells was tested by the Spearman correlation method. Datebases showed LINC01234 was up-regulated in UCEC and associated with poor clinicopathologic characteristics. What’s more quantitative real time polymerase chain reaction (qRT-PCR) analyse of clinical tissue specimens, LINC01234 was actually high expression in UCEC. The results showed an AUC of 0.726, indicating that LINC01234 had a significant diagnostic value. Further, Kaplan-Meier analysis showed that high LINC01234 expression was associated with poorer progress free interval (PFI) (hazard ratio (HR): 1.68, 95% confidence interval (CI): 1.18–2.39, p = 0.004), disease-specific survival (DSS) (HR: 2.17, 95% CI: 1.29–3.67, p = 0.004), overall survival (OS) (HR: 1.81, 95% CI: 1.19–2.75, p = 0.005). Cox regression analysis showed LINC01234 expression was an independent factor for DSS. Pathway enrichment and immune infiltration analysis showed the most likely mechanisms that LINC01234 promoted tumor progression. LINC01234 demonstrated diagnostic and prognostic potential in UCEC and was shown to exert its effects via various mechanisms, including cell proliferation, spermatogenesis, angiogenesis and immune response in the tumor microenvironment, to promote tumor progression; thus, indicating that it could be a target for treating UCEC.

LINC01234; UCEC; Diagnostic value; Prognostic value; Biomarker

[1] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA: A Cancer Journal for Clinicians. 2021; 71: 7–33.

[2] Loewer S, Cabili MN, Guttman M, Loh Y, Thomas K, Park IH, et al. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nature Genetics. 2010; 42: 1113–1117.

[3] Ouyang D, Li R, Li Y, Zhu X. A 7-lncRNA signature predict prognosis of Uterine corpus endometrial carcinoma. Journal of Cellular Biochemistry. 2019; 120: 18465–18477.

[4] Ghaffar M, Khodahemmati S, Li J, Shahzad M, Wang M, Wang Y, et al. Long non-coding RNA LINC01234 regulates proliferation, invasion and apoptosis in esophageal cancer cells. Journal of Cancer. 2018; 9: 4242–4249.

[5] White NM, Cabanski CR, Silva-Fisher JM, Dang HX, Govindan R, Maher CA. Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. Genome Biology. 2014; 15: 429.

[6] Chen X, Liu Y, Yang Z, Zhang J, Chen S, Cheng J. LINC01234 promotes multiple myeloma progression by regulating miR-124-3p/GRB2 axis. American Journal of Translational Research. 2019; 11: 6600–6618.

[7] Zhu Y, Luo C, Korakkandan AA, Fatma YHA, Tao Y, Yi T, et al. Function and regulation annotation of up-regulated long non-coding RNA LINC01234 in gastric cancer. Journal of Clinical Laboratory Analysis. 2020; 34: e23210.

[8] Chen X, Chen Z, Yu S, Nie F, Yan S, Ma P, et al. Long noncoding RNA LINC01234 functions as a competing endogenous RNA to regulate CBFB expression by sponging miR-204-5p in gastric cancer. Clinical Cancer Research. 2018; 24: 2002–2014.

[9] Zhang F, Cai H, Liu H, Gao S, Wang B, Hu Y, et al. High Expression of CISD2 in relation to adverse outcome and abnormal immune cell infiltration in glioma. Disease Markers. 2022; 2022: 1–25.

[10] Ke F, Ren C, Zhai Z, Gao X, Wei J, Zhu Y, et al. LINC01234 regulates microRNA-27b-5p to induce the migration, invasion and self-renewal of ovarian cancer stem cells through targeting SIRT5. Cell Cycle. 2022; 21: 1020–1033.

[11] Bi M, Zheng L, Chen L, He J, Yuan C, Ma P, et al. In RNA LINC01234 promotes triple-negative breast cancer progression through regulating the miR-429/SYNJ1 axis. American Journal of Translational Research. 2021; 13: 11399–11412.

[12] Lu X, Jing L, Liu S, Wang H, Chen B. MiR-149-3p is a potential prognosis biomarker and correlated with immune infiltrates in uterine corpus endometrial carcinoma. International Journal of Endocrinology. 2022; 2022: 1–15.

[13] Gao Y, Shang S, Guo S, Li X, Zhou H, Liu H, et al. Lnc2Cancer 3.0: an updated resource for experimentally supported lncRNA/circRNA cancer associations and web tools based on RNA-seq and scRNA-seq data. Nucleic Acids Research. 2021; 49: D1251–D1258.

[14] Wei S, Yu Z, Shi R, An L, Zhang Q, Zhang Q, et al. PX4 suppresses ferroptosis to promote malignant progression of endometrial carcinoma via transcriptional activation by ELK1. BMC Cancer. 2022; 22: 881.

[15] Hussein AM, Wang Y, Mathieu J, Margaretha L, Song C, Jones DC, et al. Metabolic Control over mTOR-dependent diapause-like state. Developmental Cell. 2020; 52: 236–250.e7.

[16] Li C, Hu J, Hu X, Zhao C, Mo M, Zu X, et al. LncRNA SNHG9 is a prognostic biomarker and correlated with immune infiltrates in prostate cancer. Translational Andrology and Urology. 2021; 10: 215–226.

[17] Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39: 782–795.

[18] Lu N, Liu J, Ji C, Wang Y, Wu Z, Yuan S, et al. MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancer. Bioengineered. 2021; 12: 3603–3620.

[19] Xiao F, Jia H, Wu D, Zhang Z, Li S, Guo J. LINC01234 aggravates cell growth and migration of triple-negative breast cancer by activating the Wnt pathway. Environmental Toxicology. 2021; 36: 1999–2012.

[20] Jiang X, Zhu Q, Wu P, Zhou F, Chen J. Upregulated long noncoding RNA LINC01234 predicts unfavorable prognosis for colorectal cancer and negatively correlates with KLF6 expression. Annals of Laboratory Medicine. 2020; 40: 155–163.

[21] Wang F, Bi J, Yi C, Zhang Y, Zhang Y, Yue Q. Relationship between prognosis, immune infiltration level, and differential expression of PARVG gene in uterine corpus endometrial carcinoma. Contrast Media & Molecular Imaging. 2022; 2022: 1–9.

[22] Zhang F, Cai H, Liu H, Gao S, Wang B, Hu Y, et al. High expression of CISD2 in relation to adverse outcome and abnormal immune cell infiltration in glioma. Disease Markers. 2022; 2022: 1–25.

[23] Cao W, Jiang Y, Ji X, Ma L. An immune-related risk gene signature predicts the prognosis of breast cancer. Breast Cancer. 2021; 28: 653–663.

[24] Lu X, Jing L, Liu S, Wang H, Chen B. MiR-149-3p is a potential prognosis biomarker and correlated with immune infiltrates in uterine corpus endometrial carcinoma. International Journal of Endocrinology. 2022; 2022: 1–15.

[25] Yu H, Chen C, Han F, Tang J, Deng M, Niu Y, et al. Long noncoding RNA MIR4435-2HG suppresses colorectal cancer initiation and progression by reprogramming neutrophils. Cancer Immunology Research. 2022; 10: 1095–1110.

[26] Seymour F, Cavenagh JD, Mathews J, Gribben JG. NK cells CD56bright and CD56dim subset cytokine loss and exhaustion is associated with impaired survival in myeloma. Blood Advances. 2022; 6: 5125–5159.

[27] Nong W, Huang F, Mao F, Lao D, Gong Z, Huang W. DCAF12 and HSPA1A may serve as potential diagnostic biomarkers for myasthenia gravis. BioMed Research International. 2022; 2022: 8587273.